Generic Name and Formulations:
Aztreonam 75mg/vial; pwd for inhalation via nebulization after reconstitution; preservative-free.
Gilead Sciences, Inc.
Indications for CAYSTON:
To improve respiratory symptoms in cystic fibrosis patients with Pseudomonas aeruginosa.
Adults and Children:
<7yrs: not established. Use a short-acting bronchodilator 15 minutes to 4 hours before each dose; or a long-acting bronchodilator 30 minutes to 12 hours before starting therapy. >7yrs: 75mg (1 vial) by nebulization three times daily (at least 4 hours apart) for 28 days. Use Altera Nebulizer only.
Monobactam or beta-lactam allergy. FEV<25% or >75% predicted, patients colonized with Burkholderia cepacia: safety/effectiveness not established. Pregnancy (Cat.B).
Do not mix with other drugs in nebulizer.
Cough, nasal congestion, wheezing, pharyngolaryngeal pain, pyrexia, chest discomfort, abdominal pain, vomiting, rash; chest tightness, bronchospasm, allergic reactions (discontinue if occurs).
To support and assist patients with cystic fibrosis contact the Cayston Access Program at (877) 7CAYSTON. Should be administered immediately after reconstitution. Do not reconstitute until ready to administer a dose.
Vials—84 (w. diluent)
Neurology Advisor Articles
- Erenumab Superior to Placebo for Reducing Migraine Disability, Improving HRQoL
- Congress Passes Bill to Fight Opioid Crisis
- Managing Status Epilepticus in Palliative Care: Accounting for Patient and Family Experience
- Physical Activity Decreases Vascular Comorbidities in Multiple Sclerosis
- Review of Factors Impacting Sport-Related Concussion Headaches
- Anodal tDCS Offers Possible Benefit for Improving Item Recall in Post-Stroke Aphasia
- Hospitalization Tied to Brain Abnormalities in Older Adults
- Spending Often Persists in High-Cost Medicare-Medicaid Eligible
- Skills-Based Intervention Did Not Cut Systolic BP After Stroke, TIA
- High Frequency of Headaches Following Dialysis Associated With BUN and Blood Pressure